poisar

Stocks · News reference

Ascendiant Capital Raises RenovoRx Price Target to $15.00

Fiscal.ai

Ascendiant Capital has maintained its 'Buy' rating on RenovoRx while increasing the price target for the company's shares from $14.50 to $15.00.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
fiscal.ai
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading